Biocon Biologics has secured approval from the European Medicines Agency (EMA) to manufacture biosimilar Bevacizumab at its new facility in Bengaluru, Biocon announced on Monday. This development allows Biocon Biologics to expand its manufacturing capabilities for the biosimilar, which is used in cancer treatment.
The Securities and Exchange Board of India (SEBI) is investigating Quant Mutual Fund for alleged front-running activities. Front-running is an illegal practice where trades are made based on privileged information before it is available to clients. SEBI has conducted search and seizure operations at Quant Mutual Fund’s offices in Mumbai and Hyderabad as part of the investigation.
In response to the inquiry, Quant Mutual Fund issued a note to investors late Sunday, acknowledging the SEBI investigation and assuring full cooperation with the regulator. The fund house highlighted its commitment to regulatory compliance and transparency, aiming to maintain investor confidence.
